Background: The contaminant isolated from contaminated heparin was oversulfated chondroitin sulfate (OSCS). Other possible contaminants should be evaluated. Methods: Contaminants were isolated from recalled contaminated heparin and were compared to OSCS from animal sources and to heparin by-products synthetically persulfated. Results: A great variability in molecular weight was observed in the isolated contaminants. Dermatan sulfate with high-molecular-weight in addition to OSCS was detected. Oversulfated chondroitin sulfate from different sources as well as heparin by-products produced activation of prekallikrein to kallikrein at variable rates as measured by the generation of kallikrein. All agents produced activation of the complement system. All compounds formed complexes with platelet factor 4 (PF4) and all produced 14C serotonin release in the heparin-induced thrombocytopenia (HIT) analysis. The agents also exhibited variable anticoagulant responses that were mostly mediated via heparin cofactor II. Conclusion: These results suggest that heparin contaminants represent a heterogeneous group of oversulfated glycosaminoglycans (OSGAGs) which may mediate multiple pathophysiologic responses.
Hoppensteadt DA, Wahi R., Adiguzel C., et al. Contaminant in the recalled unfractionated heparin preparations: where is the problem? Clin Appl Thromb Hemost. 2008;14(3):261-266.
2.
Ramacciotti E. , Wahi R., Messmore HLContaminated heparin preparations, severe adverse events and the contact system. Clin Appl Thromb Hemost . 2008;14(4):489-491.
3.
Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin . N Engl J Med. 2008; 359(25):2674-2684.
4.
Schwartz LBHeparin comes clean. N Engl J Med. 2008;358: 2505-2509.
5.
Fareed J., Ahluwalia M., Wahi R., Ramaccioti E., Hoppensteadt D., Bick RLContaminants in heparins continue to be unfolded. Int Angiol . 2008;27(6):457-461.
6.
Fareed J.Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recalled heparin. Semin Thromb Hemost. 2008;34(1):119-127.
7.
Guerrini M., Zhang Z., Shriver Z., et al. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A.2009 ;106(40):16956-16961.
8.
Kishimoto TK , Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457-2467.
9.
Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26(6):669-675.
10.
Bigler P., Brenneisen R.Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy . J Pharm Biomed Anal.2009;49(4):1060-1064.
11.
Volpi N., Maccari F., Linhardt RJQuantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal Biochem.2009; 388(1):140-145.
12.
Beyer T., Diehl B., Randel G., et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal. 2008;48(1):13-19.
13.
Neville GA, Mori F., Holme KR, Perlin ASMonitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. J Pharm Sci. 1989;78(2):101-104.
14.
Sitkowski J. , Bednarek E., Bocian W., Kozerski L.Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem. 2008;51(24):7663-7665.
15.
Wang L., Buchanan S., Meyerhoff MEDetection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem. 2008; 80(24):9845-9847.
16.
Spencer JA, Kauffman JF, Reepmeyer JC, et al. Screening of heparin API by near infrared reflectance and Raman spectroscopy. J Pharm Sci.2009;98(10):3540-3547.
17.
Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LFAnalysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal.2009; 49(3):670-673.
18.
Tami C., Puig M., Reepmeyer JC, et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials. 2008;29(36):4808-4814.
19.
Clark M., Hoppensteadt D., Walenga J., et al. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Int Angiol. 2008;27(5): 370-376.
20.
Bairstow S. , McKee J., Nordhaus M., Johnson R.Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products . Anal Biochem.2009;388(2):317-321.
21.
Hu P., Fang L., Chess EKSource-induced fragmentation of heparin, heparan, and galactosaminoglycans and application. Anal Chem.2009;81(6):2332-2343.
22.
Greinacher A., Warkentin TEContaminated heparin. N Engl J Med. 2008;359(12):1291-1292; ; author reply 3.
23.
Ganong WFCardiovascular homeostasis in health and disease. In: Naggi A, ed. Review of Medical Physiology, 22nd ed. New York: McGraw Hill; 2002:256-259.
24.
Deitch EAMultiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992;216(2):117-134.
25.
Li B., Suwan J., Martin JG, et al. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol.2009;78(3):292-300.
26.
Warkentin TEHeparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007;21(4):589-607, v.
27.
Adiguzel C. , Bansal V., Litinas E., et al. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin . Clin Appl Thromb Hemost.2009; 15(2):145-151.
28.
Walenga J.HIT NATF 2008NAFTonline; 2008.
29.
Kohl J.Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol. 2001;38(2-3):175-187.
30.
Ember JA, Hugli TEComplement factors and their receptors. Immunopharmacology . 1997;38(1-2):3-15.
31.
Haas PJ, van Strijp J.Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res. 2007;37(3):161-175.
32.
Lambrecht BNAn unexpected role for the anaphylatoxin C5a receptor in allergic sensitization. J Clin Invest. 2006;116(3): 628-32.
33.
Wills-Karp M.Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc Am Thorac Soc. 2007;4(3):247-251.
34.
Wills-Karp M., Koehl J.New insights into the role of the complement pathway in allergy and asthma. Curr Allergy Asthma Rep. 2005;5(5):362-369.
35.
Tollefsen D.Anticoagulants and HIT. Washington University in St. Louis Hematology/Oncology Grand Rounds 2008-2009. St. Louis: Washington University in St. Louis; 2008:1-36.
